Identification

Name
SP1049C
Accession Number
DB04978
Type
Small Molecule
Groups
Investigational
Description

SP1049C is a novel anthracycline chemotherapeutic agent designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. Preliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the oesophagus. Median survival is encouraging and correlates strongly with dose levels.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Intended for the treatment of carcinoma of the oesophagus.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

SP1049C is a novel anticancer agent containing doxorubicin and two nonionic pluronic block copolymers. Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

TargetActionsOrganism
UDNA topoisomerase 2-alphaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
AcemetacinAcemetacin may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with SP1049C.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with SP1049C.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Withdrawn
AlcuroniumSP1049C may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidSP1049C may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of SP1049C can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of SP1049C can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of SP1049C.Approved, Investigational
AmpicillinThe serum concentration of SP1049C can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of SP1049C can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumSP1049C may increase the respiratory depressant activities of Atracurium.Experimental
Atracurium besylateSP1049C may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
AzidocillinThe serum concentration of SP1049C can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of SP1049C can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of SP1049C can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
BendazacBendazac may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of SP1049C can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of SP1049C can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of SP1049C can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
Botulinum Toxin Type ASP1049C may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BSP1049C may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with SP1049C.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of SP1049C.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
CarbenicillinThe serum concentration of SP1049C can be decreased when it is combined with Carbenicillin.Approved
Carbenicillin indanylThe serum concentration of SP1049C can be decreased when it is combined with Carbenicillin indanyl.Approved
CarboplatinSP1049C may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of SP1049C can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
CisatracuriumSP1049C may increase the respiratory depressant activities of Cisatracurium.Experimental
Cisatracurium besylateSP1049C may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of SP1049C.Approved
Clodronic AcidSP1049C may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
CloxacillinThe serum concentration of SP1049C can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateSP1049C may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of SP1049C can be decreased when it is combined with Cyclacillin.Approved
CyclosporineSP1049C may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with SP1049C.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
DecamethoniumSP1049C may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with SP1049C.Approved
DiclofenacDiclofenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of SP1049C can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with SP1049C.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with SP1049C.Approved
Domoic AcidSP1049C may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideSP1049C may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
EpicillinThe serum concentration of SP1049C can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with SP1049C.Approved
EtanerceptEtanercept may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
Etidronic acidSP1049C may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of SP1049C can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of SP1049C which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of SP1049C.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with SP1049C.Approved, Vet Approved
GallamineSP1049C may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideSP1049C may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with SP1049C.Experimental
GuacetisalGuacetisal may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
IbandronateSP1049C may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of SP1049C which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with SP1049C.Experimental
LeflunomideLeflunomide may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of SP1049C.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
MecamylamineSP1049C may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of SP1049C which could result in a higher serum level.Withdrawn
MetampicillinThe serum concentration of SP1049C can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of SP1049C can be decreased when it is combined with Meticillin.Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with SP1049C.Experimental
MetocurineSP1049C may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideSP1049C may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of SP1049C can be decreased when it is combined with Mezlocillin.Approved
MivacuriumSP1049C may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of SP1049C can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinSP1049C may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with SP1049C.Experimental
OlopatadineOlopatadine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of SP1049C which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with SP1049C.Approved
OxacillinThe serum concentration of SP1049C can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Withdrawn
PamidronateSP1049C may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumSP1049C may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of SP1049C can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of SP1049C can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with SP1049C.Experimental
PhenoxymethylpenicillinThe serum concentration of SP1049C can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
PimecrolimusPimecrolimus may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
PipecuroniumSP1049C may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of SP1049C can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with SP1049C.Experimental
PirfenidonePirfenidone may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of SP1049C can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of SP1049C can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
Procaine benzylpenicillinThe serum concentration of SP1049C can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
PropicillinThe serum concentration of SP1049C can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with SP1049C.Experimental
PTC299PTC299 may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
PyrantelSP1049C may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumSP1049C may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental, Investigational
RisedronateSP1049C may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumSP1049C may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SuccinylcholineSP1049C may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of SP1049C can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of SP1049C can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
SultamicillinThe serum concentration of SP1049C can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of SP1049C can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
TazobactamThe serum concentration of SP1049C can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateSP1049C may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateSP1049C may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of SP1049C can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of SP1049C which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
TicarcillinThe serum concentration of SP1049C can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidSP1049C may increase the hypocalcemic activities of Tiludronic acid.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with SP1049C.Approved
TranilastTranilast may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of SP1049C which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
TubocurarineSP1049C may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of SP1049C.Approved
VecuroniumSP1049C may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of SP1049C which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidSP1049C may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of SP1049C which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, Brampton M, Halbert G, Ranson M: Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer. 2004 Jun 1;90(11):2085-91. [PubMed:15150584 ]
  2. Link [Link]
External Links
Not Available
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da

Drug created on October 21, 2007 16:23 / Updated on August 17, 2016 12:24